. | Baseline IGFBP7 . | Baseline and 1-year IGFBP7 . | |||||||
---|---|---|---|---|---|---|---|---|---|
Events . | HRadj (95% CI)* . | P . | C index with clinical covariates only . | C index with baseline IGFBP7 only . | C index with both (improvement from clinical covariates only) . | HRadj (95% CI)* . | P . | C index with clinical covariates only . | C index with both (improvement from clinical covariates only) . |
Sustained decline in eGFR by 40%† | 2.27 (1.05–4.93) | 0.038 | 0.73 | 0.69 | 0.73 (0) | 14.8 (7.2–30.6) | <0.001 | 0.77 | 0.79 (+0.04) |
Progression to macroalbuminuria | 2.50 (1.54–4.07) | <0.001 | 0.81 | 0.63 | 0.81 (0) | 3.80 (1.80–7.80) | <0.001 | 0.66 | 0.81 (0.01) |
First progression of albuminuria | 1.80 (1.36–2.38) | <0.001 | 0.56 | 0.56 | 0.58 (+0.01) | 1.76 (1.16–2.65) | 0.007 | 0.56 | 0.57 (+0.01) |
Cardiovascular death | 6.55 (3.93–10.9) | <0.001 | 0.66 | 0.67 | 0.69 (+0.03) | 2.69 (0.86–8.35) | 0.09 | 0.65 | 0.68 (0) |
Renal composite‡ | 3.51 (1.66–7.42) | 0.001 | 0.73 | 0.70 | 0.74 (+0.01) | 15.7 (7.68–32.0) | <0.001 | 0.77 | 0.80 (+0.04) |
Renal composite plus cardiovascular death | 4.90 (3.16–7.60) | <0.001 | 0.67 | 0.67 | 0.70 (+0.03) | 6.90 (4.10–11.7) | <0.001 | 0.68 | 0.71 (+0.01) |
Renal composite plus progression to macroalbuminuria | 3.80 (2.50–4.07) | <0.001 | 0.63 | 0.64 | 0.66 (+0.03) | 7.40 (4.50–12.2) | <0.001 | 0.68 | 0.69 (+0.02) |
. | Baseline IGFBP7 . | Baseline and 1-year IGFBP7 . | |||||||
---|---|---|---|---|---|---|---|---|---|
Events . | HRadj (95% CI)* . | P . | C index with clinical covariates only . | C index with baseline IGFBP7 only . | C index with both (improvement from clinical covariates only) . | HRadj (95% CI)* . | P . | C index with clinical covariates only . | C index with both (improvement from clinical covariates only) . |
Sustained decline in eGFR by 40%† | 2.27 (1.05–4.93) | 0.038 | 0.73 | 0.69 | 0.73 (0) | 14.8 (7.2–30.6) | <0.001 | 0.77 | 0.79 (+0.04) |
Progression to macroalbuminuria | 2.50 (1.54–4.07) | <0.001 | 0.81 | 0.63 | 0.81 (0) | 3.80 (1.80–7.80) | <0.001 | 0.66 | 0.81 (0.01) |
First progression of albuminuria | 1.80 (1.36–2.38) | <0.001 | 0.56 | 0.56 | 0.58 (+0.01) | 1.76 (1.16–2.65) | 0.007 | 0.56 | 0.57 (+0.01) |
Cardiovascular death | 6.55 (3.93–10.9) | <0.001 | 0.66 | 0.67 | 0.69 (+0.03) | 2.69 (0.86–8.35) | 0.09 | 0.65 | 0.68 (0) |
Renal composite‡ | 3.51 (1.66–7.42) | 0.001 | 0.73 | 0.70 | 0.74 (+0.01) | 15.7 (7.68–32.0) | <0.001 | 0.77 | 0.80 (+0.04) |
Renal composite plus cardiovascular death | 4.90 (3.16–7.60) | <0.001 | 0.67 | 0.67 | 0.70 (+0.03) | 6.90 (4.10–11.7) | <0.001 | 0.68 | 0.71 (+0.01) |
Renal composite plus progression to macroalbuminuria | 3.80 (2.50–4.07) | <0.001 | 0.63 | 0.64 | 0.66 (+0.03) | 7.40 (4.50–12.2) | <0.001 | 0.68 | 0.69 (+0.02) |
HRadj, adjusted HR.
Covariates for adjustment were selected using the Bayesian information criterion in patients randomized to placebo in the main study along with baseline IGFBP7 and treatment allocation. Improvement in the C index was changed above a base model of covariates excluding biomarker concentrations.
A 40% decrease in eGFR was sustained for two or more consecutive measures.
The renal composite end point from CANVAS comprised a 40% decrease in eGFR (sustained for two or more consecutive measures), the need for RRT (dialysis or transplantation), or renal death.